Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “stock status of the company's new products,” the company replied that the company's PCR-11 gene, IDH, HER2/ER/PR products are under NMPA approval, and HRD products are applying for innovative medical devices; in addition, approval for various tumor associated diagnostic products is progressing rapidly.
艾德生物(300685.SZ)：PCR-11基因、IDH、Her2/ER/PR等产品处于NMPA审批中
Ed Biotech (300685.SZ): PCR-11 gene, IDH, Her2/er/PR products are under NMPA approval
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.